Drugs / TLC-1180
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300189 | Oct 2025 → Apr 2027 expected | — | OrsoBio, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | OrsoBio, Inc | Results OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions orsobio.com ↗
The randomized, double-blind, placebo-controlled study demonstrated significant improvements in weight loss, insulin sensitivity, liver health, and body composition compared with tirzepatide monotherapy. |
| 2025-11-04 | OrsoBio, Inc | Results OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025 orsobio.com ↗
Preclinical studies demonstrate the potential of TLC-6740 and TLC-1180 to promote weight loss while preserving lean mass, alone and with incretins, in obese mice and monkeys |
| 2025-06-20 | OrsoBio, Inc | Results OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association’s 85th Scientific Sessions orsobio.com ↗
The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC-1180 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300189 ↗ |
| Route | Oral | “Oral solution of TLC-1180” NCT07300189 ↗ |